Haya Omeish, MD, Austin Mueller, DM, Syed-Mohammed Jafri, MD, Dilip Moonka, MD Henry Ford Health, Detroit, MI
Introduction: The associated risks of liver biopsy for assessing fibrosis in patients with Metabolic dysfunction-associated steatotic liver disease (MASLD) have heightened the need to validate non-invasive fibrosis scores for accuracy and efficacy. This study aims to compare the accuracy of the FIB-4 (Fibrosis-4) and Fibroscan scores in diagnosing fibrosis in MASLD patients.
Methods: A total of 116 patients were categorized into three groups based on their Fibroscan kPa (kilopascal) scores: Group I with mild fibrosis (MF), comprising F0 to F1, and Group II with moderate fibrosis (AF), comprising F2-F3, with group 3 with advanced fibrosis classified as F4.
Results: The study evaluated the correlations between Fibroscan,FIB-4 values and liver biopsy stage in various subgroups of patients. In the overall cohort (N=116), significant positive correlations were found between Fibroscan and liver biopsy stage (R=0.246, P=0.008), and liver biopsy stage and FIB-4 value (R=0.537, P< 0.001). Among males (N=55), a strong significant correlation was observed between liver biopsy stage and FIB-4 value (R=0.727, P< 0.001), though correlations involving Fibroscan were not significant. In females (N=61), significant positive correlations existed between all pairs of measures, with the strongest being between liver biopsy stage and FIB-4 value (R=0.349, P=0.006).
Age-related analysis showed that in patients younger than 65 (N=82), significant correlations were found between Fibroscan and liver biopsy stage (R=0.332, P=0.002), and liver biopsy stage and FIB-4 value (R=0.602, P< 0.001). For those aged 65 or older (N=34), only the correlation between liver biopsy stage and FIB-4 value was significant (R=0.390, P=0.023).
Racial analysis revealed that in the White race group (N=89), significant correlations were found across all measures, while in the non-White group (N=25), only the correlation between liver biopsy stage and FIB-4 value was significant (R=0.706, P< 0.001). As seen in Table-1
Discussion: Both FIB-4 and Fibroscan can be used to rule out advanced fibrosis in MASLD patients. However, a stronger relationship between liver biopsy stage and FIB-4 value was noted compared to their individual associations with Fibroscan.
Note: The table for this abstract can be viewed in the ePoster Gallery section of the ACG 2024 ePoster Site or in The American Journal of Gastroenterology's abstract supplement issue, both of which will be available starting October 27, 2024.
Disclosures:
Haya Omeish indicated no relevant financial relationships.
Austin Mueller indicated no relevant financial relationships.
Haya Omeish, MD, Austin Mueller, DM, Syed-Mohammed Jafri, MD, Dilip Moonka, MD. P4569 - How Accurate Is FIB-4 vs Fibroscan in Clinical Practice: Comparing Methodology of Liver Fibrosis Assessment, ACG 2024 Annual Scientific Meeting Abstracts. Philadelphia, PA: American College of Gastroenterology.